Form 8-K - Current report:
SEC Accession No. 0000950170-25-090202
Filing Date
2025-06-26
Accepted
2025-06-26 08:45:30
Documents
14
Period of Report
2025-06-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20250620.htm   iXBRL 8-K 72391
2 EX-4.1 tcrt-ex4_1.htm EX-4.1 150184
3 EX-5.1 tcrt-ex5_1.htm EX-5.1 29076
4 EX-10.1 tcrt-ex10_1.htm EX-10.1 318399
5 GRAPHIC img65855275_0.jpg GRAPHIC 5456
  Complete submission text file 0000950170-25-090202.txt   772201

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250620.xsd EX-101.SCH 28388
16 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250620_htm.xml XML 4700
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 251075206
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)